The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone-Reference-Cited by-同舟云学术

The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone

Published:2007-08 Issue:1-3 Volume:94 Page:99-106
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Buckley Peter F.,Harvey Philip D.,Bowie Christopher R.,Loebel Antony

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference32 articles.

1. Remission in schizophrenia: Proposed criteria and rationale for consensus;Andreasen;Am. J. Psychiatry,2005

2. Type of symptom remission and treatment outcomes in the long-term treatment of patients with schizophrenia;Ascher-Svanum;Neuropsychopharmacology,2005

3. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia;Buchanan;Schizophr. Bull.,2005

4. A new view of therapy for cognition in schizophrenia;Carpenter;Biol. Psychiatry,2002

5. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients;Cornblatt;Psychiatry Res.,1989

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Symptomatic remission and its associated factors among patients with schizophrenia on risperidone or olanzapine at Amanuel mental specialized hospital, Addis Ababa, Ethiopia;Middle East Current Psychiatry;2024-07-05

2. Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system;Translational Psychiatry;2023-03-27

3. Impact of Cognitive Disturbances and Clinical Symptoms on Disability in Patients with Paranoid Schizophrenia: A Study of a Bulgarian Clinical Sample;International Journal of Environmental Research and Public Health;2023-01-30

4. It takes two to tango: Widening our understanding of the onset of schizophrenia from a neuro-angiogenic perspective;Frontiers in Cell and Developmental Biology;2022-08-24

5. Neurocognition, functional outcome, and quality of life in remitted and non-remitted schizophrenia: A comparison with euthymic bipolar I disorder and a control group.;Schizophrenia Research;2022-02